Informations:
Erreur:
ID
15275
Description
Intensity Modulated Radiation Therapy - Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00188513
Lien
https://clinicaltrials.gov/show/NCT00188513
Mots-clés
Versions (1)
- 24/05/2016 24/05/2016 -
Téléchargé le
24 mai 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Prostatic Neoplasms NCT00188513
Eligibility Prostatic Neoplasms NCT00188513
- StudyEvent: Eligibility
Similar models
Eligibility Prostatic Neoplasms NCT00188513
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
adenocarcinoma
Item
histologic diagnosis of adenocarcinoma of the prostate within six months of entry
boolean
C0001418 (UMLS CUI [1])
staging
Item
clinical stage t1b, t1c, t2a-c nx mo (see appendix 1 for staging). any gleason score is eligible for entry, but gleason score must be determined.
boolean
C0027646 (UMLS CUI [1])
C3203027 (UMLS CUI [2])
C3203027 (UMLS CUI [2])
PSA and gleason score
Item
patients with a psa >10.0 and gleason score of 7; or patients with any psa value and gleason score of >8 must have clinically negative lymph nodes as determined by a pelvic ct scan done within 12 weeks of entry. a negative bone scan is required before entry for all patients with gleason score >8, or any patient with a gleason score of 7, and a psa >10.
boolean
C3203027 (UMLS CUI [1])
C0138741 (UMLS CUI [2])
C0024204 (UMLS CUI [3,1])
C1513916 (UMLS CUI [3,2])
C0138741 (UMLS CUI [2])
C0024204 (UMLS CUI [3,1])
C1513916 (UMLS CUI [3,2])
cytotoxic anticancer therapy
Item
the patient must not have received any cytotoxic anticancer therapy. previous or concurrent hormonal therapy for local disease is acceptable.
boolean
C0677881 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C0279025 (UMLS CUI [2])
ecog performance status
Item
ecog performance status of 1 or less
boolean
C1520224 (UMLS CUI [1])
age
Item
age 80 years old or less
boolean
C0001779 (UMLS CUI [1])
serum psa
Item
serum psa <25 ng/ml within 4 weeks of study entry
boolean
C2123607 (UMLS CUI [1])
informed consent
Item
informed consent
boolean
C0021430 (UMLS CUI [1])
inflammatory bowel disease
Item
patients with history of inflammatory bowel disease or other contraindication to radical radiation therapy
boolean
C0021390 (UMLS CUI [1])
C1522449 (UMLS CUI [2,1])
C1301624 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,1])
C1301624 (UMLS CUI [2,2])
colorectal surgery
Item
patients with prior colorectal surgery
boolean
C0543467 (UMLS CUI [1])
pelvic radiotherapy
Item
any prior pelvic radiotherapy. any prior turp done <12 weeks from study entry.
boolean
C0436276 (UMLS CUI [1])
cytotoxic chemotherapy
Item
any previous cytotoxic chemotherapy
boolean
C0677881 (UMLS CUI [1])
prior malignancy
Item
patients with prior malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer
boolean
C0006826 (UMLS CUI [1])